CRIS stock forecast, quote, news & analysis
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas... Show more
Why Curis (CRIS) Stock Is Down -17.8% in the Last 30 Days
Key Takeaways
- Curis (CRIS) shares fell roughly 17.8% over the trailing 30 days, from about $0.80 in early October to approximately $0.66.
- The decline was driven primarily by a dilutive $8.5 million private placement announced on October 16, 2026, priced at $0.51 per share with accompanying warrants at $0.60.
- Over the broader quarter, the stock has fallen from around $5.15 in early August, pressured by multiple dilutive financings and ongoing cash-burn concerns.
- Curis's investment thesis centers on emavusertib, its oral IRAK4 and FLT3 inhibitor in development for primary CNS lymphoma (PCNSL) and chronic lymphocytic leukemia (CLL).
- The company reported positive updated PCNSL data in July 2026, and initial CLL combination data from 5–10 patients is expected in December 2026.
- Proceeds from the October placement are intended to fund operations through that initial CLL data readout.
- For additional detail, review Curis's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven trading strategies are tracking this and other tickers.
Curis (CRIS) Company Overview and Market Position
Curis, Inc. is a clinical-stage biotechnology company focused on emavusertib (CA-4948), an orally available, small-molecule inhibitor of IRAK4 and FLT3. Emavusertib is being evaluated in the TakeAim Lymphoma Phase 1/2 study in combination with the BTK inhibitor ibrutinib in patients with relapsed or refractory primary CNS lymphoma, and in the TakeAim CLL Phase 2 study in combination with the BTK inhibitor zanubrutinib in chronic lymphocytic leukemia. Curis licenses emavusertib through its 2015 collaboration with Aurigene Discovery Technologies. The drug has received Orphan Drug Designation from the U.S. FDA for PCNSL, AML, and MDS, and from the European Commission for PCNSL. As a pre-revenue, development-stage company with a single lead asset, Curis's valuation is closely tied to clinical data, regulatory progress, and its ability to secure capital.
Curis (CRIS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CRIS declined from a closing price of $0.8034 on October 2, 2026, to approximately $0.66 in early November, a move of about -17.8%. The decline was concentrated around mid-October, when shares fell sharply on a dilutive financing announcement, followed by a partial rebound into month-end.
The quarterly picture is steeper. From a close near $5.15 in early August 2026, shares have fallen to roughly $0.66, a decline of approximately 87% over the period. This multi-month downtrend reflects successive equity financings at progressively lower prices, ongoing cash burn, and a shrinking capitalization, even as the company continued to advance its clinical programs.
What Drove CRIS Stock Price in the Last 30 Days
The dominant catalyst was Curis's October 16, 2026 announcement of an approximately $8.5 million private placement. The company agreed to sell 16,666,680 shares, or pre-funded warrants in lieu of shares, together with common warrants, at an effective combined price of $0.51 per share. The common warrants carry a $0.60 exercise price, become exercisable six months after issuance, and expire five and a half years later. Curis also agreed to reduce the exercise price of certain January 2026 and August 2026 warrants to $0.60 per share.
Because the placement was priced below the prevailing market level and included substantial warrant coverage, it signaled additional dilution to existing shareholders, pressuring the stock in the days following the announcement. The company stated that proceeds would fund research and development and general corporate purposes, and would be sufficient to fund operations through its initial CLL data in 5–10 patients expected in December 2026. Shares subsequently staged a partial recovery into late October as the near-term financing overhang was absorbed.
What Drove CRIS Stock Performance Over the Last Quarter
The quarterly decline reflects a broader pattern of capital raising at declining valuations. In August 2026, the company completed a financing that included warrants with a $1.75 exercise price, contributing to a sharp selloff that took the stock from roughly $5 in early August to about $1.60 by mid-August. This was followed by the October placement at $0.51 per share, compounding dilution concerns.
On the fundamental side, Curis reported positive updated data in July 2026 from its TakeAim Lymphoma study in PCNSL, including a 100% overall response rate among BTKi-naïve evaluable patients and a 26% response rate among BTKi-experienced patients. The company also advanced its TakeAim CLL program, dosing its first patients and reaffirming a December 2026 data milestone. These clinical updates provided a supportive backdrop, but financing risk and cash-runway concerns outweighed the pipeline progress over the quarter.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots from a much larger universe of strategies covering thousands of tickers. Only top-performing and most relevant bots appear in this section, giving traders a focused view of strategies that are currently standing out. The bots vary widely in approach, timeframe, and performance metrics, so investors can compare different trading styles rather than relying on a single signal. For those interested in data-driven market analysis beyond individual stock coverage, this section offers a practical way to monitor how algorithmic strategies are positioned.
CRIS Stock Forecast Drivers: What Investors Should Watch Next
The most important near-term event is the initial CLL data readout, expected in December 2026, covering 5–10 patients from the TakeAim CLL study of emavusertib in combination with zanubrutinib. Updated PCNSL data from the TakeAim Lymphoma study is expected in the first half of 2027 and could support potential regulatory filings for accelerated approval. Investors should also monitor the company's cash position and any further financing activity, given its pre-revenue status and ongoing research and development spending. Additional considerations include progress toward regaining compliance with Nasdaq listing requirements and broader biotech-sector sentiment. These factors carry meaningful risk and are not guarantees of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CRIS's Stochastic Oscillator is remaining in oversold zone for 1 day
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on CRIS as a result. In 57 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +67.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRIS advanced for three days, in 137 of 181 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for CRIS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 12 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
CRIS moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRIS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CRIS broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CRIS entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.468) is normal, around the industry mean (3.498). P/E Ratio (0.248) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (3.280) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.301) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. CRIS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRIS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a drug company
Industry Biotechnology